---
title: Explore how organoid screen enables efficient testing of KRAS inhibitors & combination therapies
description: New research reveals how patient-derived organoids are reshaping KRAS-targeted drug development. Get a first look at the data from our AACR 2025 poster.
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# Explore how organoid screen enables efficient testing of KRAS inhibitors & combination therapies

New research from HUB Organoids® reveals how patient-derived organoids are reshaping KRAS-targeted drug development. Get a first look at the data from our AACR 2025 poster.

**50 other researchers like you have already downloaded this poster. Don’t miss out!**

download poster

## Get human insights into your preclinical drug development

![section-img2](https://resources.huborganoids.nl/hs-fs/hubfs/section-img2.png?width=483&height=508&name=section-img2.png)

KRAS remains one of the most notorious oncogenes in cancer—frequently mutated, clinically significant, and historically “undruggable.” But that’s changing.

In our latest study, we tested eight KRAS inhibitors across a diverse panel of over 20 patient-derived organoids (PDOs) from colorectal, pancreatic, and lung cancers—each harboring different KRAS mutations.

## What you'll learn:

- How PDOs reflect real-world tumor diversity across CRC, PDAC, and NSCLC
- Results from testing 8 KRAS inhibitors across 20+ organoid models
- Why Tipifarnib shows broad activity—and how resistance in KRASG12C mutants can be overcome
- The role of EGFR inhibition in boosting KRAS inhibitor response

download poster

## Looking to begin your KRASi Organoid Screen?

Share your screening parameters and get an instant quote

[connect with an expert](https://www.huborganoids.nl/kras-inhibitor-testing-organoid-solutions/)

![section-img3](https://resources.huborganoids.nl/hs-fs/hubfs/section-img3.png?width=600&height=478&name=section-img3.png)

×

### Download poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*